glp·helper
glphelper.com/wegovy/delaware/dover
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® providers &
prescriptions in Dover, DE

Verified Wegovy providers in Dover, DE. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Wegovy weight loss →trial-anchored estimate
city providers
37
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Delaware
37 of 37 shown

Find an Wegovy provider in Delaware.

Every entry is checked against the NPI registry and the Delaware medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Delaware city · /wegovy/delaware/{city}
§ 03Getting Wegovy in Dover
37 providers · Dover, DE

How to get Wegovy in Dover.

37 GLP-1 prescribers and 7 local resource types are on record for Dover, plus 1 nearby town in the directory.

Prescribers in Dover
37 prescribers
37 GLP-1 prescribers in Dover, most listed as Family Medicine (15), Internal Medicine (12) and Internal Medicine, Endocrinology, Diabetes & Metabolism (10). Any Delaware-licensed physician, nurse practitioner, or PA can prescribe Wegovy, over video or in person. The nearest towns on record are Wilmington (38 providers).
Around the prescription in Dover
7 listed nearby
6 dietitians, 1 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 2 places to move are on record near Dover.
Medicaid (weight loss)
Covered
As of April 2026, Delaware Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Delaware’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

At a glanceNDC 0169-4525
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon. Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Delaware

Diagnosed diabetes reaches 11.1% of adults in Delaware.

of Delaware adults have obesity
36.6%
diagnosed diabetes
11.1%

Age-adjusted estimates for Delaware, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossOzempic babies explained
§ 05Support around Wegovy in Dover
1 nutritionists

The prescription is one part. Here is the rest, in Dover.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Dover, DE, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Monica Mccollin, CNS, LDN, RYT
NUTRITIONIST
Nutritionist · Education
8 The Grn Ste B
Call 202-441-8239NPI 1861080194

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Planet Fitness
GYM
4.4 on Google · 675 reviews
1005 N State St
Website
Club Fitness Dover
GYM
4.0 on Google · 339 reviews
650 S Bay Rd #18
Website
CNU Fit - Dover
TRAINING
4.9 on Google · 209 reviews
1404 Forrest Ave #9
Website
BreakThrough Personal Coaching & Wellness
FITNESS
4.9 on Google · 170 reviews
1255 S State St Ste 10
Website
Ignite Fitness Kickboxing
FITNESS
4.9 on Google · 155 reviews
35 Commerce Way
Website
CrossFit Dover
GYM
5.0 on Google · 151 reviews
155 Commerce Way
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Wegovy weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses; usually transient and dose-dependent
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$1,300 to $1,500
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $400
per month copay
Varies by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)
Typically denied
Most plans exclude weight-loss medications from formulary
Medicare Part D
Not covered
Statutory exclusion of weight-loss drugs in original Medicare[5]
Manufacturer savings card
as low as $0
per month for 12 mo
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Wegovy providers in Delaware

NPI-verified Wegovy (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Wegovy in other states

Find NPI-verified Wegovy (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Wegovy in Delaware

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]